Cancer

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox

Phase 1/2 Clinical Trial of TNX-801 for the Prevention of Mpox and Smallpox to Commence Following Submission of an IND…

1 year ago

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent…

1 year ago

Cancer Partners of Nebraska to Elevate Patient Engagement With the ‘Unified Digital Patient Experience’ Platform by Willowglade Technologies

LAS VEGAS, NV / ACCESSWIRE / August 21, 2023 / Cancer Partners of Nebraska, a leading healthcare provider specializing in…

1 year ago

Mindbio Therapeutics First Batch of MB22001 has Been Manufactured and is Ready for Use in World First Phase 2 Take at Home Psychedelic Clinical Trials

MB22001 has been manufactured ready for use in Phase 2 clinical trialsWorld first take-home approvals for psychedelic microdosingVANCOUVER, BC /…

1 year ago

72-Provider FQHC Implements eClinicalWorks Population Health Solutions for Improved Screening and Compliance

eClinicalWorks population health solutions streamline patient data for Connecticut Institute for Communities, Inc.WESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud EHR,…

1 year ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development…

1 year ago

Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency…

1 year ago